Comparative analysis of gene expression profiles of papillary thyroid microcarcinoma and papillary thyroid carcinoma by Kim, Hoon Yub et al.
452 Journal of Cancer Research and Therapeutics - October-December 2010 - Volume 6 - Issue 4
Hoon Yub Kim,  
Woong-Yang Park1, 
Kyu Eun Lee2, 
Won Seo Park3, 
Yoo Seung Chung4, 




























Comparative analysis of gene expression 
profiles of papillary thyroid microcarcinoma 
and papillary thyroid carcinoma
ABSTRACT
Purpose: Papillary thyroid carcinomas (PTCs) measuring 1.0 cm or less were separately defined as papillary thyroid microcarcinomas 
(PTMs) by the World Health Organization, emphasizing on their benign behavior. However, some reported that PTMs may have aggressive 
behavior, can cause regional, or even distant metastases. But till now, the characteristics of PTMs were only reviewed and described 
by the clinicopathological parameters, and no analysis of PTM by the gene level is available. We report on the gene expression profiles 
of PTMs by the oligonucleotide microarrays and the results of comparative analysis with those of PTCs.
Materials and Methods: The gene expression profiles of 25 pairs of PTMs and their normal thyroid tissue counterparts, and 11 pairs 
of PTCs and their normal counterparts, were analyzed by Affymetrix Human Genome U133A. Data were analyzed by the SAM and the 
DAVID 2008 program to detect differentially expressed genes in supervised sample classification.
Results: Two-hundred thirteen statistically significant up-regulated genes and –183 significant down-regulated genes of PTMs 
compared with their normal counterpart thyroid tissues, which were mainly cell adhesion-related genes and immune response genes, 
were detected. Two-hundred sixty-one up-regulated and –157 down-regulated genes of PTCs were also detected. In the comparative 
analyses of gene expression profiles of PTMs and PTCs, no significant difference was found.
Conclusion: PTM should not be considered as the simple occult indolent thyroid cancer, but as the earlier stage of disease which 
eventually evolves into PTC, because the gene expression profiles of PTMs were not different from those of PTCs.
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INTRODUCTION
Thyroid carcinoma represents 1% of all malignant 
diseases and accounts for nearly 90% of 
neuroendocrine malignancies. Papillary thyroid 
carcinomas (PTCs) are the most common malignant 
thyroid tumors, representing 80-90% of thyroid 
malignancies. According to the World Health 
Organization (WHO), PTCs measuring 1.0 cm or 
less in diameter are separately defined as papillary 
thyroid microcarcinomas (PTMs), emphasizing 
on their benign behavior, probably of little clinical 
significance, which do not affect patients’ survival.[1,2]
The clinical behavior of PTMs is usually indolent as 
it was considered historically. In one series,[3] 93% 
of the patients were free of disease during a follow-
up of 3–23 years, with a mean of 6.3 years, and 
there was no single instance of distant metastases. 
However, rarely PTMs may have aggressive 
behavior,[4] can cause locoregional recurrences,[5,6] 
and cervical lymph node metastases.[7-9] The lack of 
long-term randomized prospective studies makes 
it very difficult to establish which therapeutic 
approach is better and explains the present 
uncertainty and controversies for the management 
of PTMs.
The genome-wide microarray analysis enabled us 
to obtain comprehensive gene expression profiles 
related to phenotypic and biological information in 
cancer cells[10-16] and to identify multiple applicable 
targets for the development of novel anti-cancer 
drugs and/or diagnostic markers. For the thyroid 
carcinoma, only a few reports are available on the 
results of this novel approach, mainly focusing on 
the identification of unknown molecules involved 
in the carcinogenic pathway especially from 
the differentiated carcinoma to the anaplastic 
carcinoma, and the identification of the new 
markers to discriminate the follicular carcinoma 
and the benign follicular adenoma.[11,17-20]
All the genome-wide microarray analyses of PTCs 
to date is those of the relatively large size tumors, 
that is larger than 2 cm in diameter, and there is no 
result available on the gene expression profiles of 
PTMs which might show different clinical behaviors 
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from PTCs. Thus we performed the oligonucleotide microarray 
analysis of the PTMs to reveal the gene expression profiles 
of PTMs and compared the results with those of the PTCs to 
give valuable information on the decision of the therapeutic 
approaches to the PTMs.
MATERIALS AND METHODS
This study was approved by the institutional review board of 
the Seoul National University Hospital, Seoul, Korea (registered 
number: H-0706-048-211).
Eighty PTC and PTM tissue samples, along with 80 normal 
thyroid tissue samples were obtained with written informed 
consent from the patients undergone total thyroidectomy and 
neck dissection under the diagnosis of papillary carcinoma at 
the Department of Surgery, Seoul National University Hospital. 
These cancer tissues were histopathologically diagnosed as 
classic papillary carcinoma, and atypical variants such as tall 
cell, columnar cell, insular, or follicular variants were excluded.
The 0.2 cm sized cube of cancer tissue was obtained from the 
center of the cancer lesion immediately after the lobectomy of 
the pathologic lobe of the thyroid gland, and the 0.2 cm sized 
cube of normal thyroid tissue was obtained from the center 
of the normal contralateral lobe in the same patient just after 
the completion of the contralateral lobectomy. Each samples 
were embedded in RNA later solution immediately after the 
sampling and stored at 4°C overnight for the isolation of RNA 
in the next day.
After the isolation of RNA, the purity and quality of the samples 
were evaluated with a ND-1000 spectrometer (Nanodrop 
Technologies) and Bioanalyzer Nano Labchips (Agilent 
Technologies). When the RNA signal pattern was identical to 
that of the control sample and the ratio of 28s/18s rRNA was 
more than 1.0, the paired cancer and normal thyroid tissues 
were included and undergone the microarray procedure, 
otherwise excluded. Finally 72 paired cancer and normal 
tissues from the 36 patients, including 50 PTM along with 
normal tissues from the 25 PTM patients and 22 PTC along 
with normal tissues from the 11 PTC patients, were included 
for the study.
The Affymetrix Human Genome U133 Plus 2.0 GeneChip 
arrays were used for microarray hybridizations. This GeneChip 
comprises >54,000 probe sets and analyzes the expression 
level of >47,000 transcripts. For microarray hybridization, we 
followed the protocol described in the Affymetrix GeneChip 
eukaryotic two cycles target preparation protocol (Affymetrix). 
For the first-round synthesis of double-stranded cDNA, 100 
ng of total RNA were reverse transcribed using the two-cycle 
cDNA synthesis kit (Affymetrix, Santa Clara, CA) and T7-
oligo-dT primer according to the manufacturer’s instructions 
followed by IVT amplification with the MEGAscript T7 kit 
(Ambion, Inc., Austin, TX). After cleanup of the cRNA with a 
GeneChip sample cleanup module IVT column (Affymetrix), 
second-round double-stranded cDNA was amplified using the 
IVT labeling kit (Affymetrix). A 20 μg aliquot of the labeled 
product was fragmented by heat and ion-mediated hydrolysis 
at 94°C for 35 min in H
2
O and 8 μl of 5× fragmentation 
buffer (Affymetrix). The fragmented cRNA was hybridized for 
16 h at 45°C in a hybridization oven 640 to a U133 Plus 2.0 
oligonucleotide array (Affymetrix). The washing and staining 
of the arrays with phycoerythrin-conjugated streptavidin 
(Molecular Probes, Eugene, OR) were completed in a fluidics 
station 450 (Affymetrix). The arrays were then scanned using 
a confocal laser GeneChip scanner 3000 (Affymetrix). For the 
data analysis, global normalization at a target value of 500 was 
applied to each of the 72 arrays under consideration using the 
GeneChip operating software (Affymetrix). Normalized data 
from text files were imported to a Microsoft Excel spreadsheet.
To find out the commonly over- or under-expressed, in other 
words, up- or down-regulated genes in the cancer tissue 
compared with normal tissue through the intra-individual 
analyses, we performed significance analysis of microarrays 
(SAM, Version 3.0, 2007, www-stat.stanford.edu/~tibs/
SAM/). After the identification of the statistically significant 
genes from the SAM plotsheet and Delta table, we performed 
functional annotation bioinformatic analysis using the 
Database for Annotation, Visualization and Integrated 
Discovery 2008 (DAVID 2008, david.abcc.ncifcrf.gov) program, 
and selected the statistically significant genes by their function 
and names with a Benjamini cutoff value <0.05. Then the 
nonsupervised hierarchial clustering was performed.
RESULTS
The gene expression profiles of the 72 paired cancer and 
normal tissues from the 36 patients, including 50 PTM along 
with normal tissues from the 25 PTM patients and 22 PTC 
along with normal tissues from the 11 PTC patients, were 
analyzed. The mean patient age was 51.3 years (range, 33-71). 
There were 25 females and 11 males. The mean tumor size was 
0.92 cm (range, 0.3-2.4). Regional lymph node metastasis was 
observed in 16 patients, extrathyroidal extension of the cancer 
in 24 patients, and multifocal cancer in 12 patients. Overall, 12 
patients were diagnosed as stage I and the other 24 patients 
were stage III, according to the American Joint Committee on 
Cancer Staging, 6th edition [Table 1].
Among the 25 PTM patients, regional lymph node metastasis 
was observed in 10 patients, and TNM stage I was in 10 
patients, and III was in 15 patients. Multifocal cancer was 
observed in 8 patients out of 25 PTM patients. Among the 11 
PTC patients, regional lymph node metastasis was observed 
in 6 patients, and TNM stage I was in 2 patients and III was in 
9 patients. Multifocal cancer was observed in 4 patients out 
of 11 PTC patients.
In the analysis of the gene expression profiles of PTMs, after the 
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SAM, statistically significant 1688 up-regulated genes and 2543 
down-regulated genes, in total 4231 genes, were obtained at 
the Delta value 3.05 and false discovery rate (FDR) < 0.05 from 
the PTMs and their paired normal thyroid tissue array results.
After the functional annotation analysis of these genes using 
the DAVID program, 213 significant up-regulated genes in 
PTMs, which belongs to the 12 functional categories described 
in [Table 2], were selected at the Benjamini cutoff value <0.05. 
In turn, 183 significant down-regulated genes in PTMs, which 
belongs to the four functional categories described in Table 3, 
were also selected at the Benjamini cutoff value <0.05. The 
lists of significant genes selected are not shown here owing 
to the limited space of the journal.
In the analysis of the gene expression profiles of PTCs, as in the 
analysis of PTM profiles, after the SAM, statistically significant 
1319 up-regulated genes and 1742 down-regulated genes, in 
total 3061 genes, were obtained at the Delta value 1.70 and 
FDR < 0.05 from the PTCs and their paired normal thyroid 
tissue array results.
And after the functional annotation analysis of these genes 
using the DAVID program, 261 significant up-regulated genes 
in PTCs, which belongs to the 13 functional categories, were 
selected at the Benjamini cutoff value <0.05. In turn, 157 
significant down-regulated genes in PTCs, which belongs to 
the 7 functional categories, were also selected at the Benjamini 
cutoff value <0.05. The lists of significant genes and functional 
categories selected are also not shown here.
To evaluate the difference between the gene expression profiles 
of PTMs and PTCs, we applied several analytic methods in the 
following.
First, Figure 1 is the heatmap of the dissimilarity matrix 
between PTMs and PTCs. We selected 1825 gene probe sets 
from the microarray data in which variations of the expression 
signal intensities between the samples were maximal, and 
colorized the distance between the samples using those 
genes. If the similarity of gene expression profiles between 
the samples increases, the distance between the samples is 
small, and it is colored blue in the heatmap. If the similarity 
between the samples decreases, it turns red. As seen in the 
figure, the similarity of the samples does not correlate with 
the classification of PTM and PTC. In other words, PTMs and 
PTCs could not be differentiated by gene expression profiles.
Second, Figure 2 is the two-dimensional projection of 
distances between PTMs and PTCs. We projected the results 
of the distance matrix of the samples in two dimensions, 
and if the similarity of gene expression profiles between the 
samples increases, the samples shall be located closer in the 
projection. PTMs are indicated with black circles and PTCs 
with golden circles in the figure. PTMs and PTCs do not make 
any cluster and located irregularly after the projection as in 
Table 1: Clinicopathologic features of the cancer samples 
used for microarray analyses
Characteristics Value
Patient’s age (yrs)





















According to the American Joint Committee on Cancer Staging, 6th edition.
Table 2: Functional categories of genes up-regulated in 
papillary thyroid microcarcinoma
Cluster Count P-value Benjamini
Collagen 23 2.5E-5 1.1E-3
Cytoskeletal protein binding 61 1.2E-5 3.9E-3
Integrin 14 2.3E-5 1.0E-3
GTPase regulator activity 56 1.9E-5 6.1E-3
Tyrosine-protein kinase 23 4.4E-5 1.7E-3
Transmembrane receptor protein 
tyrosine kinase activity
17 1.4E-4 3.3E-2
Trimer 13 4.0E-7 3.0E-5
Triple helix 13 3.2E-6 2.3E-4
Hydroxylysine 13 4.6E-6 2.7E-4
EF hand 13 8.2E-4 2.0E-2
Phosphoric monoester hydrolase 15 7.8E-4 1.9E-2
Table 3: Functional categories of genes down-regulated in 
papillary thyroid microcarcinoma
Cluster Count P-value Benjamini
FAD binding 20 2.9E-5 1.4E-3
Flavoprotein 30 1.8E-6 1.5E-4
Methyltransferase activity 33 3.5E-4 4.4E-2
Oxidoreductase 98 8.3E-7 7.4E-5
Figure 1: Heatmap of the dissimilarity matrix between papillary thyroid 
carcinoma and papillary thyroid microcarcinoma samples
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the figure, assuming that the similarity of the samples in 
the gene expression level does not correlate to the PTM/PTC 
classification.
Third, Figure 3 shows the four different dendrograms of the 
samples from the various hierarchial clustering algorithms – 
complete linkage, single linkage, Ward method and divisive 
clustering. Cluster in the dendogram represents the relative 
similarity of the gene expression profiles of the samples 
included in. As shown in the figure, even though using the 
various different methods, PTMs and PTCs could not be divided 
by the gene expression profiles.
In Figure 4, statistical significance of each cluster from the 
Ward method hierarchial clustering described in Figure 3 is 
expressed on multiscale bootstrap resampling. The numbers 
indicate two statistical supporting values: red number denotes 
AU (Approximately Unbiased) value and green number 
indicates BP (Bootstrap Probability) value. The clusters with 
AU larger than 95% are highlighted by rectangles, which 
are strongly supported by data. In the rectangle significant 
clusters, PTMs and PTCs coexist, also implying that PTMs and 
PTCs cannot be divided by the gene expression profiles.
DISCUSSION
Recently, the proportion of PTMs increased rapidly owing 
to widespread use of thyroid ultrasonography. It has been 
considered that PTM shows a benign behavior and has a high 
likelihood of remaining silent during the lifetime. However, 
several recent studies showed that the recurrence rate of 
PTM was not negligible and there existed cases with distant 
metastases or fatal outcome.
Noguchi, et al., from an analysis of 867 patients affected by 
PTM, concluded that total thyroidectomy is not necessary and 
that modified radical lymph node dissection is not necessary 
unless macroscopic lymph node metastases are present.[21] Ito, 
et al. addressed the issue of whether operation for PTMs is 
needed.[22] They started an observational trial in 162 patients 
with PTM diagnosed by FNAC who volunteered not to have 
surgery and found that more than 70% of tumors either did not 
change or decreased in size with respect to baseline. In 10% 
of the cases the tumor diameter increased above 1 0mm, and 
in 1.2% of the cases lymph node metastases appeared during 
follow-up. In the control group of 626 patients with PTM who 
were treated by surgery, 50.5% had lymph node metastases 
and multifocality was present in 42.8%; during the follow-
up, the recurrence rate was of 2.7% at 5 years and 5.0% at 8 
years. These authors concluded that PTM was frequently not 
progressing and that patients could choose the observation.
In contrast with these Japanese authors, Hay, et al. performed a 
multivariate analysis of 535 PTM patients with a mean follow-
up of 17.5 years and reported that 27 patients had recurrence, 
and the authors found that risk factors for locoregional 
recurrence were lymph node metastases at presentation 
and extent of initial thyroid surgery.[23] Baudin, et al., in their 
Figure 2: Two-dimensional projection of distances between papillary 
thyroid carcinoma and papillary thyroid microcarcinomas
Figure 3: Four different dendrograms, clustering of papillary thyroid 
carcinoma and papillary thyroid microcarcinoma
Figure 4: Hierarchical clustering based on multiscale bootstrap 
resampling
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multivariate analysis, confirmed that multifocality and extent 
of initial surgery were significant risk factors for recurrence.[9] 
Both these studies therefore underlie the importance of total or 
near-total thyroidectomy and lymph node dissection in PTMs 
presenting with lymph node metastases.
As above, many controversies on the management of PTMs 
coexist to date and it is very difficult to decide which 
therapeutic approach is better. This might not only be due to 
the absence of long-term randomized prospective studies, but 
also might be due to the lack of the information on the PTMs 
compared with PTCs in the molecular level.
Thus we analyzed the gene expression profiles of PTMs, which 
have never been reported before, and compared those with 
PTCs to provide the basic evidence for the treatment of PTMs.
Most of the commonly up-regulated and down-regulated 
genes in PTMs were functionally associated cell adhesion and 
cell-mediated immunity. These functional annotation analytic 
results of PTMs showed almost no difference in comparison 
with those in PTCs in this study.
Ezlinger et al recently meta-analyzed most of the previously 
published microarray-based gene expression profiles of thyroid 
carcinomas, and reported 67 significantly up-regulated and 
down-regulated genes commonly expressed in PTCs.[24] We 
used these genes for hierarchial clustering of our PTMs and 
their normal tissue counterparts [Figure 5]. As seen in Figure 
5, cancers and normal tissues were well separately clustered 
implying that the quality of our collected tissue, the procedures 
of our microarray experiment and the resulted data were quite 
reliable. However, in direct comparison of the above previously 
reported 67 genes of PTCs and 261 significant genes of PTMs 
from our study, only 6 up-regulated genes (MMP13, TMSB4X, 
S100A4, S100A6, IGF2R, COL1A1) and 1 down-regulated gene 
(TPO) were matched. This might be due to the usage of old 
generation microarray chips, such as Affymetrix GeneChip 
Human Genome U95 which lack in the number of transcript 
probes, in the most of the previous reports. Another important 
reason of this discrepancy might be due to the fact, as Ezlinger, 
et al. mentioned in their article, in most of the previous studies 
authors performed inter-individual (unpaired) analysis defining 
the reference tissue as non-nodular healthy tissue or benign 
tumor tissue which might be interfered by the bias caused 
by the difference between the individuals and the reference 
tissues. Compared with these studies, our data and results 
would be more reliable because we performed intra-individual 
(paired) analysis using the newest generation gene chips.
As shown in [Figures 1–4], PTMs and PTCs show no difference 
in gene expression level. Thus we can assume that PTM should 
not be considered as the simple occult indolent thyroid cancer, 
but as the earlier stage of disease which eventually evolves 
into PTC. 
Most PTMs will slowly be progressed into PTCs; however, some 
PTMs will show aggressive behavior causing regional or even 
distant metastases in their earlier presentation. To date, we 
still cannot predict these biological behaviors of PTMs. Thus 
it would be important to find out the genes that may help 
to predict which of the PTMs will behave aggressively in the 
future study.
CONCLUSION
PTM should not be considered as the simple occult indolent 
thyroid cancer, but as the earlier stage of disease which 
eventually evolves into PTC, because the gene expression 
profiles of PTMs were not different from those of PTCs.
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